Neoepitope derived from tumor-specific mutated protein

Neoepitopes derived from tumor-specific mutated proteins are short peptide fragments created when genetic alterations, such as point mutations, insertions, deletions, or gene fusions, in tumor DNA are translated into abnormal proteins[1][4][6]. These peptides are processed and presented on the tumor cell surface by major histocompatibility complex (MHC) molecules, creating unique, non-self antigens that can be recognized as foreign by the immune system, particularly by T cells[1][2][3]. This recognition enables the immune system to selectively target and kill cancer cells, forming the scientific rationale for technologies such as personalized cancer vaccines and adoptive T-cell therapies targeting these neoepitopes[2][3][4][5][6]. Unlike most traditional therapeutic targets, neoepitopes are not static proteins but peptide-MHC complexes whose sequence and immunogenicity are individualized based on each patient's tumor mutations. Therapeutic strategies involving neoepitopes aim to amplify or introduce T-cell responses against these cancer-specific targets, but face challenges including complex and patient-specific identification, tumor heterogeneity, immune tolerance, and potential cross-reactivity with normal tissues[3][4][5][6].

Other names

Tumor-specific neoantigenCancer neoepitopeMutation-derived neoepitope

Elicit T-cell mediated immune response against tumor cells displaying the neoepitope Induction of cytotoxic CD8+ T lymphocyte response following MHC-I presentation Stimulation of CD4+ T cell response via MHC-II presentation (in some cases)